Price Disclosure (pre - 1 December 2010)
Please note: The information on this page is no longer current and is only included here for historical reference.
Current information is maintained on the Price Disclosure (SPD) page.
- Price Disclosure Requirements
- Drugs currently under price disclosure
- How to send in your price disclosure submission
- Submission templates, examples and forms
- Summary of Price Reductions for Drugs Subject to Price Disclosure pre-1 December 2010
- Summary of Drugs and Manners of Administration Subject to Price Disclosure pre-1 December 2010
Price Disclosure Requirements
Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.
Price disclosure requirements under Part VII of the National Health Act 1953 commenced on 1 August 2007. Under those requirements the responsible persons for some multiple-brand medicines are required to provide information to the Department of Health & Ageing, including their revenue for supply of those brands of medicine to wholesalers and approved pharmacists, and the volume of sales. Price disclosure information provided to the Department will be used to determine whether there will be a price reduction. Price reductions that result from price disclosure will apply to every brand that has the same drug with the same manner of administration as those brands for which price disclosure information was provided.
Until 1 January 2011 price disclosure requirements and any associated price reductions apply to pharmaceutical items that have drugs in Part A of F2. Thereafter those requirements and any associated price reductions will apply to pharmaceutical items that have drugs on the consolidated F2 list.
Further detail about the price disclosure requirements is contained within the following documents:
- Pharmaceutical Benefits Scheme Price Disclosure Requirements, July 2007 (PDF 158 KB)
- Pharmaceutical Benefits Scheme Price Disclosure Procedural and Operational Guidelines, July 2007 (PDF 1323 KB)
- Pharmaceutical Benefits Scheme Price Disclosure Quick Reference Guide, August 2007 (PDF 287 KB)
- Pharmaceutical Benefits Scheme Price Disclosure Assurance Activities (PDF 28 KB)
Drugs currently under price disclosure
Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.
This page lists those drugs where a brand of a pharmaceutical item is subject to price
disclosure requirements and assists responsible persons to identify the relevant reporting
periods and due dates for those drugs.
To identify the reporting period and due dates for a manner of administration of a
drug, follow the steps outlined below:
1. Identify the listing date of the first mandatory brand for the drug and manner
of administration in Table 1 (note: it is important to consider the manner of administration
as a single drug can have more than one set of reporting periods and due dates);
2. Based on the listing month of the first mandatory brand(s), identify the reporting
periods in Table 2; and
3. Based on the listing month of the first mandatory brand(s), identify the due dates
for price disclosure information in Table 3.
Table 1 below is current for all listings up until 1 November 2010. Further drugs may be added to the list at any time.
Drug | Manner of Administration | Listing Date of First Mandatory Brand(s) |
---|---|---|
Alendronic acid | Oral | 1 Dec 2007 |
Alendronic acid with colecalciferol | Oral | 1 July 2009 |
Amisulpride | Oral | 1 Aug 2007 |
Azithromycin | Oral | 1 Aug 2009 |
Bicalutamide | Oral | 1 Aug 2008 |
Bisoprolol | Oral | 1 Aug 2009 |
Cabergoline | Oral | 1 Aug 2009 |
Carvedilol | Oral | 1 Apr 2008 |
Cefalotin | Injection | 1 Aug 2008 |
Ceftriaxone | Injection | 1 Nov 2007 |
Cisplatin | Injection | 1 Oct 2008 |
Clopidogrel | Oral | 1 Apr 2010 |
Doxorubicin | Injection/Intravesical | 1 Aug 2007 |
Enalapril with hydrochlorothiazide | Oral | 1 Apr 2008 |
Escitalopram | Oral | 1 June 2009 |
Famciclovir | Oral | 1 June 2010 |
Fluconazole | Oral | 1 Oct 2007 |
Fluconazole | Injection | 1 Dec 2007 |
Fludarabine | Injection | 1 Dec 2008 |
Fosinopril with hydrochlorothiazide | Oral | 1 Aug 2007 |
Gemcitabine | Injection | 1 Apr 2009 |
Glucose | Injection | 1 Aug 2009 |
Irinotecan | Injection | 1 Apr 2008 |
Levetiracetam | Oral | 1 June 2010 |
Levodopa with Carbidopa | Oral | 1 Sept 2010 |
Meloxicam | Oral | 1 Aug 2007 |
Memantine | Oral | 1 Apr 2010 |
Mitozantrone | Injection | 1 Aug 2007 |
Morphine | Oral | 1 Aug 2009 |
Naltrexone | Oral | 1 Dec 2007 |
Octreotide | Injection | 1 Dec 2007 |
Ondansetron | Injection | 1 Aug 2007 |
Ondansetron | Oral | 1 May 2009 |
Oxaliplatin | Injection | 1 July 2009 |
Oxazepam | Oral | 1 Aug 2010 |
Oxybutynin | Oral | 1 Aug 2007 |
Paclitaxel | Injection | 1 Jan 2009 |
Perindopril with indapamide | Oral | 1 Aug 2007 |
Prochlorperazine | Oral | 1 Aug 2010 |
Risperidone | Oral | 1 Dec 2008 |
Sodium Chloride | Injection | 1 Aug 2009 |
Sodium Lactate Compound | Injection | 1 Aug 2009 |
Sumatriptan | Oral | 1 Feb 2008 |
Topiramate | Oral | 1 Oct 2009 |
Valproic acid | Oral | 1 Aug 2007 |
Vancomycin | Injection | 1 Dec 2007 |
Vinorelbine | Injection | 1 Mar 2009 |
Listing Month of First Mandatory Brand(s) | 1st Quarterly Reporting Period | 2nd Quarterly Reporting Period | 3rd Quarterly Reporting Period | 4th Quarterly Reporting Period | Incentive Reporting Period |
---|---|---|---|---|---|
1 January 1 February 1 March 1 April |
1 May – 31 July | 1 August – 31 October | 1 November – 31 January | 1 February – 30 April | 1 May – 30 April |
1 May 1 June 1 July 1 August |
1 September – 30 November | 1 December – 29 February | 1 March – 31 May | 1 June – 31 August | 1 September – 31 August |
1 September 1 October 1 November 1 December |
1 January – 31 March | 1 April – 30 June | 1 July – 30 September | 1 October – 31 December | 1 January – 31 December |
#Responsible persons must begin collecting monthly data from the date of listing for mandatory brands and from the beginning of the month following the election to volunteer to disclose for voluntary brands. The responsible person may be required to collect and submit more or less than three months of data for the initial period of reporting. Thereafter the responsible person is required to collect and submit three months of data each quarterly reporting period. Further information is contained within the National Health (Pharmaceutical Benefits) Regulations and in the PBS Price Disclosure Procedural and Operational Guidelines.
If you are unsure about the reporting periods and due dates for a manner of administration of a drug, or the information you should provide for a particular brand please contact the Department by sending an email to pricedisclosure@health.gov.au or by calling (02) 6289 7335.
Listing Month of First Mandatory Brand(s) | 1st Quarterly Reporting Period | 2nd Quarterly Reporting Period | 3rd Quarterly Reporting Period | 4th Quarterly Reporting Period and Incentive Reporting Period |
---|---|---|---|---|
1 August | 1 February each year | 1 May each year | 1 August each year | 1 November each year |
1 September | 1 June each year | 1 September each year | 1 December each year | 1 March each year |
1 October | 1 June each year | 1 September each year | 1 December each year | 1 March each year |
1 November | 1 June each year | 1 September each year | 1 December each year | 1 March each year |
1 December | 1 June each year | 1 September each year | 1 December each year | 1 March each year |
1 January | 1 October each year | 1 January each year | 1 April each year | 1 July each year |
1 February | 1 October each year | 1 January each year | 1 April each year | 1 July each year |
1 March | 1 October each year | 1 January each year | 1 April each year | 1 July each year |
1 April | 1 October each year | 1 January each year | 1 April each year | 1 July each year |
1 May | 1 February each year | 1 May each year | 1 August each year | 1 November each year |
1 June | 1 February each year | 1 May each year | 1 August each year | 1 November each year |
1 July | 1 February each year | 1 May each year | 1 August each year | 1 November each year |
If you are unsure about the reporting periods and due dates for a manner of administration of a drug, or the information you should provide for a particular brand please contact the Department by sending an email to pricedisclosure@health.gov.au or by calling (02) 6289 7335.
For a list of Items Exempt from Price Disclosure Requirements, click on this link.
How to send in your price disclosure submission
Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.
For CD/DVD submissions
- Complete the appropriate forms and templates that are available on this site.
- Save the data in the selected format, and burn to a CD/DVD.
- Label the CD/DVD so the Department can easily match it to your Declaration form.
- Send the data and Price Disclosure Declaration form to the address below.
For paper based submissions
- Complete the appropriate forms and templates that are available on this site.
- Send the data and Price Disclosure Declaration form to the address below.
Send to:
Price Disclosure Team
High Cost Drugs/Price Disclosure
Pharmaceutical Evaluation Branch
MDP 952
Department of Health
GPO Box 9848, Canberra ACT 2601
The Department recommends that you use Registered Post.
Enquiries
For enquiries please contact:
Tel: +61 2 6289 7335
Email: pricedisclosure@health.gov.au
Submission templates, examples and forms for price disclosure
Please note: The information on this page is no longer current and is only included here for historical reference. Up to date information can be found on the Price Disclosure (EAPD) page.
Below are the forms and templates you will need to submit information for Price Disclosure.
For CD/DVD submissions
Documents you will need to complete and submit:
Price Disclosure Submission Declaration (PDF 157 KB)
Data to be provided on the following template:
Price Disclosure Template (Excel 27 KB)
Sample template:
Price Disclosure Sample (Excel 28 KB)
For paper based submissions
Complete and submit:
Price Disclosure Submission Form (PDF 155 KB)
Data dictionary
The data dictionary is a detailed description of the data fields in the templates you are filling in.